Abstract
P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have